Browsing Tag
X4 Pharmaceuticals
3 posts
Will mavorixafor’s EU path mirror its U.S. regulatory breakthrough in WHIM syndrome?
X4 Pharmaceuticals (NASDAQ: XFOR) wins EMA backing for mavorixafor. Explore what EU approval could mean for revenue, risk, and rare disease strategy.
X4 Pharmaceuticals (NASDAQ: XFOR) gets FDA fast track for mavorixafor in chronic neutropenia
X4 Pharmaceuticals (XFOR) secures FDA Fast Track for mavorixafor in chronic neutropenia, targeting trial completion in 2025 and results in 2026.
X4 Pharmaceuticals completes merger with Arsanis to advance rare disease and cancer treatments
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases…